Company Encyclopedia
View More
name
Industrial Hemp
CP20071.HK
News
View More

Grandshores Technology Group Updates CEO Emoluments

Grandshores Technology Group Limited has released supplemental information on CEO emoluments for fiscal years ending March 2019, 2020, and 2021. The announcement details remuneration for Mr. Wang Qian, CEO and co-CEO during this period, without altering previous annual reports.

Tip Ranks·
HK
01647
0.00%
Tip Ranks·
HK
01647
0.00%

Grandshores Technology Schedules Board Meeting for Interim Results

Grandshores Technology Group Limited (HK:1647) has scheduled a board meeting for November 28, 2025, to approve interim results for the six months ending September 30, 2025, and discuss an interim dividend. This meeting is crucial for stakeholders as it will shed light on the company's financial performance and potential dividend payouts, influencing investor confidence and market positioning. The company, incorporated in the Cayman Islands, operates in the technology sector and is listed on the Hong Kong Stock Exchange.

Tip Ranks·
HK
01647
0.00%
Tip Ranks·
HK
01647
0.00%

SIHUAN PHARM has signed a cooperation agreement with the American company AbaloneBio to jointly develop a new generation of innovative therapies for weight loss and muscle gain, further deepening its layout in the GPCR target field

SIHUAN PHARM has signed a cooperation agreement with the American company AbaloneBio. Both parties will jointly develop a new generation of obesity treatment drugs, aiming to enhance energy expenditure and increase muscle mass by targeting metabolism-related G protein-coupled receptors (GPCRs). This collaboration will combine Abalone's antibody screening technology with SIHUAN PHARM's research and development resources in the field of metabolic diseases, aiming to optimize obesity treatment solutions, reduce research and development risks, and promote efficient project advancement

Zhitong·
HK
00460
-4.41%
Zhitong·
HK
00460
-4.41%

LIFETECH SCI announced the two-year follow-up results of the Phase II and Phase III clinical studies of the IBS® absorbable drug-eluting coronary stent system

LIFETECH SCI announced the two-year follow-up results of its IBS® absorbable drug-eluting coronary stent system from the Phase II and III clinical studies. The study showed that the late lumen loss in the Phase II trial group was 0.28mm, compared to 0.23mm in the control group, achieving non-inferiority for the primary endpoint. In the Phase III study, the two-year target lesion failure (TLF) rate post-implantation was 5.5%, with only 5 cases of stent thrombosis occurring, resulting in a thrombosis event rate of 0.5%. This stent is the world's first fully biodegradable iron-based absorbable coronary stent, featuring good biocompatibility and ease of operation

Zhitong·
HK
01302
+0.54%
Zhitong·
HK
01302
+0.54%

Zhitong Hong Kong Stock Shareholders' Equity Disclosure | October 27

On October 27, 2025, 51 Credit Card, Yongsheng Services, CENT UNIT HLDG, and C CARBONNEUTRAL conducted the latest shareholder equity disclosure. | Stock Name | Institution Name | Nature | Shares Before Change | Shares After Change | Shareholding Ratio | | ------------------ | ------------------------ | ---------- | ---------------------- | --------------------- | ---------------------- | | 51 Credit Card | EasternGate SPC | Good Position | 101 million shares | 0 shares | 0% (latest) | 6.20% (previous) | | Yongsheng Services| Lin Zhubo | Good Position | 500,000 shares | 600,000 shares | 0.03% (latest) | 0.03% (previous) | | CENT UNIT HLDG | Yan Fei | Good Position | 500,000 shares | 0 shares | 0% (latest) | 0.09% (previous) | | C CARBONNEUTRAL | Legit Aiming Limited | Good Position | 70 million shares | 0 shares | 0% (latest) | 11.84% (previous) | Note: Changes in shareholding may be due to rights issues, consolidations, stock splits, etc. Please verify against actual circumstances

Zhitong·
HK
01372
+3.33%
HK
01959
+2.94%
Zhitong·
HK
01372
+3.33%
HK
01959
+2.94%
Posts
View More